| 0.0569 -0.019 (-25.13%) | 11-19 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.12 |
1-year : | 0.16 |
| Resists | First : | 0.11 |
Second : | 0.14 |
| Pivot price | 0.09 |
|||
| Supports | First : | 0.05 |
Second : | 0.04 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.1 |
| MA(100) : | 0.23 |
MA(250) : | 0.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 14.7 |
| RSI | RSI(14): 19.6 |
|||
| 52-week | High : | 2.69 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VVOS ] has closed below the lower bollinger band by 11.0%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.07 - 0.07 | 0.07 - 0.07 |
| Low: | 0.05 - 0.06 | 0.06 - 0.06 |
| Close: | 0.06 - 0.06 | 0.06 - 0.06 |
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Mon, 16 Nov 2026
Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Mon, 16 Nov 2026
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update - Quantisnow
Mon, 16 Nov 2026
Vivos Therapeutics, Inc. (VVOS) Q3 FY2026 earnings call transcript - Yahoo Finance
Mon, 26 Oct 2026
Ralph Elias Green receives 12,000 Vivos Therapeutics (VVOS) options with a $0.18 exercise price. - Stock Titan
Tue, 18 Aug 2026
Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... - Yahoo Finance
Mon, 17 Aug 2026
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 1.901e+007 (%) |
| Held by Institutions | 11.5 (%) |
| Shares Short | 1,630 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.076e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -121.8 % |
| Operating Margin | -93.7 % |
| Return on Assets (ttm) | -56.2 % |
| Return on Equity (ttm) | -8 % |
| Qtrly Rev. Growth | 2.09e+007 % |
| Gross Profit (p.s.) | 5.53 |
| Sales Per Share | 92.89 |
| EBITDA (p.s.) | 2.05397e+006 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.06 |
| Dividend | 0 |
| Forward Dividend | 2.36e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |